Zai Lab shares rose in premarket trading Friday after the company said that it reported positive data from its phase 1 trial evaluating its small cell lung cancer treatment.
Shares rose 7.3% ahead of the morning bell to $23.65.
The biopharmaceutical company said Friday that its experimental drug, zocilurtatug pelitecan, showed high tumor response rates and a favorable safety profile. This was when combined with an immunotherapy treatment in patients receiving initial care for advanced small cell lung cancer.
"The high confirmed response rate, encouraging durability, and well-tolerated safety profile we are seeing with a standard chemotherapy-free regimen are particularly compelling," said President and Head of Global Research and Development Rafael Amado.
The company said that it is preparing to begin a global phase 3 trial of the drug as well as an immuno-oncology regimen to explore other potential combinations.
Comments